KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets hard-to-treat pancreatic cancer gene mutation
Disease control Recruiting nowThis study tests an experimental pill called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation and have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and con…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 09:40 UTC
-
New pill targets tough cancers: early trial launches for KRAS G12C tumors
Disease control Recruiting nowThis early-phase study tests a new daily pill, D3S-001, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to check safety and find the right dose. About 442 participants will take the drug alone or with other treatments.…
Matched conditions: KRAS P.G12C
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
New hope for lung cancer patients who can't have standard treatment
Disease control Recruiting nowThis study tests a drug called sotorasib in people with stage III lung cancer that has a specific genetic change (KRAS G12C) and cannot be treated with standard chemo and radiation together. About 19 participants will receive the drug to see if it can stop the cancer from growing…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated May 26, 2026 09:33 UTC